This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by de Gasparo, M. Search for Related Content PubMed PubMed Citation Articles by de Gasparo, M. Social Bookmarking                         What's this?

New basic science initiatives with the angiotensin II receptor blocker valsartan

Novartis Pharma AG, Basel, Switzerland, m.de_gasparo@ bluewin.ch

Angiotensin II (Ang II) plays a key role in the regulation of blood pressure and fluid homeostasis. Valsartan is a highly selective Ang II receptor blocker that specifically and selectively blocks Ang II at the AT₁-receptor. In animal models, valsartan has shown positive effects on vasoconstriction, proliferation, remodelling, endothelial function and thrombogenesis, inflammation and atherosclerosis. These data are likely to be confirmed by the results of current clinical trials and valsartan is set to provide improved cardiovascular therapy in the future.

Key Words: AT1-receptor blocker • vasoconstriction • cell proliferation • preclinical data • endothelial dysfunction • cholesterol uptake

References

• Pool J., Oparil S., Hedner T. et al. Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker. Clin Ther 1998;20:1106-14.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Shetty SS, DelGrande D. Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan. J Pharmacol Ext Ther 2000; 294:179-86.
• Tong CF,Ying WY, Hua RY et al. Effect of valsartan and captopril in rabbit carotid injury: possible involvement of bradykinin in the antiproliferative action of the renin-angiotensin blockade. JRAAS (in press).
• Prescott MF, Webb RL, Reidy MA Angiotensin converting enzyme inhibition versus angiotensin II AT1 receptor antagonist. Amer J Pathol 1991;139:1291-6.[Abstract]
• Ledingham JM, Laverty R. Remodelling of resistance arteries in genetically hypertensive rats by treatment with valsartan, an angiotensin II receptor antagonist. Clin Exp Pharmacol Physiol 1996;23:576-8.[Web of Science][Medline] [Order article via Infotrieve]
• Loging JA, New RB, Baicu SC et al. Effects of angiotensin type-I receptor blockade on pericardial fibrosis. J Surg Res 1999;87:101-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sironi L., Calvio AM,Arnaboldi L. et al. Effect of valsartan, an AT1-receptor antagonist, on angiotensin II-induced PAI-1 biosynthesis in smooth muscle cells. Hypertension (in press).
• De La Heras N., Vazques-Pérez S., Navarro-Cid J. et al. Angiotensin II type 1 receptor antagonism prevented the effects of hypercholesterolemia on plasma fibrinolytic balance in rabbits. High Blood Pressure Council, Washington October 2000. Hypertension 2000; 36:694 (abstract).
• Mervaala EM, Muller DN, Park JK et al. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 1999;33: 389-95.[Abstract/Free Full Text]
• Hilgers KF, Hartner A., Porst M. et al. Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury: role of the angiotensin II type 1 receptor. Kidney Int 2000;58:2408-19.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• de las Heras N.,Aragoncillo, P., Maeso R. et al. AT(1) receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits. Hypertension 1999;34: 969-75.[Abstract/Free Full Text]
• Scheidegger KJ, Butler S., Witztum JL Angiotensin II increases macrophage-mediated modification of low-density lipoprotein via a lipoxygenase-dependent pathway. J Biol Chem 1997; 272:21609-15.[Abstract/Free Full Text]
• de Gasparo M., Hess P., Nuesslein-Hildesheim B. et al. Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction. JRAAS 2000;1;151-8.[Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 1, No. 2 suppl, S3-S5 (2000)
DOI: 10.3317/jraas.2000.052


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by de Gasparo, M. Search for Related Content PubMed PubMed Citation Articles by de Gasparo, M. Social Bookmarking                         What's this?